With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

See which workplaces made this year's list.

GPTW_Healthcare_Large_2024-DaVita, Inc_US1__20240712184600_5

<p>Employees say:</p><p>"There is a focus on making sure everyone has fun, gets to connect, feels valued, excepted, welcomed, and appreciated. The company and the employees live by its Core Values and Mission Statements."</p>

Best Large Workplaces in Health Care

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

WMAC-2021-DaVita

This year’s Fortune 500 marks the 67th running of the list.

Warren Buffett's Berkshire Hathaway is DaVita's largest shareholder, with a 33% stake in the company according to a recent filing. Buffett's faith in the company, a long-term holding, has been rewarded, as the company has delivered a 13% annual return to shareholders over the past decade. Patients from around the world come to DaVita's 2,500 treatment centers for kidney dialysis.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-230-Davita

Based in Denver, Colo., the health provider delivers dialysis treatment and other medical services to patients globally. Through DaVita Kidney Care, the company treats patients with kidney disease.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Best Workplaces In Health Care

Founded

Industry Vertical

Sites

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

DaVita, incorporated in 1994 and based in Denver, was known as DaVita HealthCare Partners Inc. until changing its name to DaVita Inc. in 2016. It provides kidney dialysis services in the U.S., operating dialysis centers and providing related lab services. In addition the company offers integrated care and disease management services, clinical research programs, physician services, and comprehensive kidney care.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

DaVita (DVA): Company Profile, Stock Price, News, Rankings

legacy

DaVita

davita

evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita First Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period.

Mr. Eliason, you may begin your conference, sir.

Thank you, and welcome to our first quarter conference call. I'm Nick Eliason, Group Vice President of Investor Relations, and joining me today are Javier Rodriguez, our CEO and Joel Ackerman, our CFO. Please note that during this call, we will make forward looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward looking statements. For further details concerning these risks and uncertainties, please refer to our first quarter earnings press release and our SEC filings, including our most recent annual report on Form 10 ks, all subsequent quarterly reports on Form 10 Q, and other subsequent filings that we make with the SEC.

Our forward looking statements are based on information currently available to us, and we do not intend and undertake no duty to update these statements except as may be required by law. Additionally, we'd like to remind you that during this call, we will discuss some non GAAP financial measures. A reconciliation of these non GAAP measures to the most comparable GAAP financial measures is included in our earnings press release furnished to the SEC and available on our website. I will now turn the call over to Javier Rodriguez.

Thank you, Nick, and thank you for joining the call today. With the conclusion of the first quarter and reflecting on the events of this past few weeks, it is clear once again the strength and dedication of our caregivers shine through each new challenge. We're in the midst of remediating a cybersecurity incident that disrupted portions of our operations. Despite these challenges, we remain steadfast. We continue delivering life sustaining care, creating meaningful career paths for our teammates, and returning value to our shareholders.

Today, I'll share information on the cyber incident, highlight our first quarter results, discuss key policy developments, and close with our outlook for the balance of the year. But first, as always, we will begin with a clinical highlight, the true foundation of everything we do. Last year, we launched a community based collaboration with the YMCA to support chronic kidney disease education and prevention. Through the collaborative community kidney health program, YMCA locations nationwide are helping to bring vital education, pre chronic disease screenings, and critical kidney health resources directly to the communities that need it the most. Our early results are eye opening.

In our initial pilot, thirty percent of participants screened were found to have previously undiagnosed CKD, creating powerful opportunities for early intervention and life changing care. Early detection and education are the cornerstones of kidney disease prevention. And through this collaboration, we're setting ambitious goals to reach thousands of people, empowering communities with the knowledge they need to close the gap in kidney health awareness. Partnership with the YMCA is more than just a program. It's a reflection of our unwavering commitment to building a healthier, stronger tomorrow.

Before getting into the first quarter performance, I wanna address the cybersecurity incident we disclosed last month. On April 12, we identified and swiftly began addressing a cybersecurity incident that encrypted parts of our system and affected our operations. While it's deeply troubling that bad actors continue to target the health care community, the incident highlighted our team's unwavering commitment to patient care. I'm grateful to report that we provided uninterrupted dialysis care for our patients on the day we detected the incident and every day since at all of our centers worldwide. Thanks to the incredible responsiveness of our teams and our investment in IT infrastructure, we've been able to restore most functions as of today.

All of our major systems used for the patients, physicians, and teammates, including the lab and billing, are up and running. Work on the remaining applications will continue over the next few weeks. While the restorations of our system is nearly complete, there will be some regulatory and legal follow ups to address as we work to identify the extent and nature of the data that was taken and make the required notices. We expect that the majority of the costs related to this incident will be one time items recognized in the second quarter, and our current expectations regarding the financial impact are included in our guidance today. Transitioning to the first quarter performance, adjusted operating income and adjusted earnings per share came in slightly ahead of our expectations.

At a high level, this was driven by outperformance within patient care costs, phosphate binders, and our international business. This favorability was partially offset by a modest underperformance in treatment volume, partially due to an abnormally high flu season. Let me offer some additional color on phosphate binders, which contributed to positive results for the quarter. As a reminder, phosphate binders are oral drugs prescribed to help dialysis patients avoid mineral bone disease. Beginning this year, CMS transitions phosphate binders from Medicare Part D into the dialysis benefit.

VITA dispensing these drugs per physician orders and receiving reimbursement from CMS and Medicare Advantage plans on a per script basis during the initial TDAPA period. As we predicted last quarter, the largest source of variability would be in drug mix, where we have seen higher than expected prescriptions of iron based binders. This is a win for our patients who are receiving the most effective medication for their individual clinical needs. We're still in the early days of this transition and expect further variability over the course of the year. That said, with initial data on drug mix, we now expect the full year operating income contribution from phosphate binders to be at the upper end of our previous guidance range of zero to positive $50,000,000.

I'll offer one final note for the first quarter regarding capital allocation. Our priority remains to invest available capital in innovation and high return growth opportunities, such as our recent Latin America acquisition. Beyond those opportunities, we remain committed to returning capital to our shareholders through share repurchases. Since our last earnings call, we repurchased approximately $680,000,000 of stock, representing an accelerated pace over this time frame. 2025, we expect share repurchases will be more front loaded than typical and should slow down over the remaining of the year.

To be clear, our capital allocation strategy remains unchanged. Now I'd like to shift gears and share some thoughts on the new administration and potential policy changes. By the fast moving environment, our top priority remains the same, advocating for our patients at the state and federal levels. Today, I'll focus on three policy topics impacting the broader health care landscape, tariffs, Medicaid, and enhanced premium tax credits. For the first two, although the policies fluid on each and there's a lot to learn, we don't currently believe either tariffs or Medicaid reform represent any material financial impact.

As it relates to qualified health plans and enhanced premium tax credits, we previously shared a cumulative operating income impact of 75 to a hundred and $20,000,000. This impact is cumulative over three years and assumes a full expiration of the enhanced premium tax credit. We continue to believe this reflects the most likely range of outcomes. And as we've shared, we're likely trending toward the higher end of that range due to a strong 2025 open enrollment for exchange plans. While we're grateful to be largely insulated from recent policy development, we remain vigilant and committed to strong patient advocacy.

In addition to outlook, We're maintaining our 2025 guidance range for adjusted operating income and adjusted earnings per share as disclosed last quarter. Although we've experienced headwinds from the cyber incident, our strong first quarter operating performance has put us in a good position to achieve our financial guidance for the full year. I will now turn the call over to Joel to discuss our financial performance and outlook in more detail.

Thank you, Javier. First quarter adjusted operating income was $439,000,000 adjusted EPS was $2 and free cash flow was negative $45,000,000 Adjusted operating income was above the guidance we gave last quarter, largely as a result of strong expense management, profitability from orals in the bundle at the high end of our range and strong performance in international, partially offset by lower than expected treatments. I'll focus first on the details behind our Q1 operating income performance, followed by an update for 2025 guidance. U. S.

Treatments per day declined 40 basis points versus the first quarter of twenty twenty four and was approximately 50 basis points below our forecast. Weakness was largely the result of higher missed treatment rate, which was caused by a severe flu season and a higher than expected impact from storms in January and February. Adding to this shortfall was the negative impact on census from higher than anticipated flu mortality in the quarter. Admission growth was strong during the quarter, which supports our hypothesis that the negative admissions growth we saw in the fourth quarter was the result of normal variability and not a trend. Looking forward to the remainder of the year, the flu related census impact in the first quarter will contribute to lower treatment volume for the remainder of the year than we had previously expected.

Additionally, we believe the cyber incident that Javier described resulted in lower than normal admissions for about two weeks in April. Taking these two factors together, combined with the treatment shortfall in Q1, we are now expecting an approximately 50 basis point decline in treatments for the year. As a reminder, 2025 volume is also negatively impacted by the PD supply shortage we faced in Q4 twenty twenty four. Despite these temporary challenges, we still expect to return to 2% volume growth, although the timing is hard to predict. Consistent with what we have forecasted in the past, these forecasts are for number of treatments, not treatments per day or non acquired growth.

Revenue per treatment increased $4 in the quarter. Approximately $10 of increase is attributable to new reimbursement for phosphate binders, partially offset by $5 of decline due to typical seasonality of patient responsibility for co pays and deductibles in the first quarter. Patient care cost per treatment increased by $7 sequentially. This was driven by approximately $8 per treatment of new cost associated with phosphate binders and partially offset by a decline from the seasonally high fourth quarter. First quarter G and A costs declined by $33,000,000 sequentially, again, as a result of a decline from typical seasonally elevated spend toward the end of the year.

Adjusted international OI increased by $29,000,000 versus the fourth quarter. As a reminder, the fourth quarter was impacted by a $19,000,000 reserve recorded against aged accounts receivable in Brazil. Integrated Kidney Care, our value based care business had operating losses of $29,000,000 in the quarter in line with expectations. As a reminder, IKC has seasonally stronger operating performance in the second half of the year. This quarter, we realigned the operations of an IT product from our IKC segment into our U.

S. Other ancillary segment, which moved approximately $4,000,000 of operating loss from IKC into U. S. Other ancillary results for the quarter. We anticipate the full year impact of this change to be approximately $17,000,000 Below the OI line, we incurred $18,000,000 of other loss, mostly related to Mozark, our joint investment with Medtronic.

We expect this to be a consistent quarterly run rate for the remainder of the year. In the first quarter, we repurchased 3,700,000.0 shares and we repurchased an additional 1,700,000.0 shares since the end of the quarter. Our repurchases continue to be informed by our typical assessment of leverage ratio, liquidity and market price relative to our view of intrinsic value. This accelerated purchase pace brought our leverage level at the end of the quarter to 3.27 times, near the middle of our target leverage range. Q1 debt expense was $135,000,000 Beginning in the second quarter, we anticipate debt expense will increase to approximately $145,000,000 per quarter for the remainder of the year.

Let me now turn to our expectations for full year 2025. We are reiterating our full year adjusted operating income and earnings per share guidance. Despite challenges associated with a difficult flu season in Q1 and expectations for some headwinds related to the recent cyber incident, the underlying strength of our business performance in the first quarter and the increase in our forecast for profitability of orals in the bundle give us confidence in our full year guidance. That concludes my prepared remarks for today. Operator, please open the call for q and a.

Thank you, sir. Our first caller is Andrew Mock with Barclays. You may go ahead, sir.

Hi, good afternoon. Appreciate all the color on the cyber attack and treatment growth. If we take the if we look at the 50 basis point revision for the full year, can you help us understand how much of that was attributable to flu in the first quarter? And how much of that is attributable to the cyber attack? And then similarly, what was the impact of flu in the quarter?

Sure, Andrew. So starting on the full year, the biggest impact on the full year was flu, but not because of the first quarter. It's really a census decline in the first quarter that impacts the full year. So that's a little bit more than half of the 50 basis points. The other two components are one, mistreatment rate in Q1, and the third would be the admit, the roughly call it 500 admissions we think we lost in a couple of weeks as a result of the cyber.

And those two are roughly equal in size. So that's the 50 basis points for the year. If you're thinking about Q1, the miss was largely mistreatment rate. The census impact in quarter did not have a impact. And the mistreatment rate was a combination both of storms in January and February, as well as flu.

Got it. Okay. And I think I heard you say that the majority of the costs related to the cyber attack will be one time items recognized in the second quarter. Can you just help us understand that? Are you going to adjust that out of earnings?

Or will you be incurring those costs and absorbing that into guidance?

So I think there'll be two different buckets. There will be some that are direct costs that we will non GAAP and are likely covered by insurance. So those are not included in our adjusted OI forecast. There will also be some that are more indirect, and those will flow through the P and L, and we've included those in our guidance.

Got it, that's helpful. And then on the oral phosphate, can you provide a bit more color on what you saw in the quarter with respect to uptake and drug mix, if you have any incremental details on that? Thanks.

Yeah, thanks, Andrew. What we saw was that the mix came in a little leaning toward the iron base. And so that's, what we said in the opening remarks that in essence change the guidance to the upper end. We had said zero to 50,000,000, and now we will look to be on the higher end of that.

Do you expect the mix to change or evolve for the balance of the year? Do you think you have a pretty good understanding of what that looks like based on results so far?

It's our first quarter with this experience. But when we talk to physicians, it appears that they're happy with the current mix.

Got it. Okay. And maybe one last one for me. Can you help us understand where commercial mix came in, in the quarter and how the exchange growth shook out for Q1? Thanks.

Sure. The mix was unchanged, flat in the low 11 percentage, and the open enrollment was, healthy. And so we continue the trajectory of growth similar to the rest of the market. Thanks for all the color. Thank you, Andrew.

Our next caller is Joanna Gajuk with Bank of America. You may go ahead.

Hi. Thank you guys for taking our question. This is Christian Porter on for Joanna. Just a few questions from us. I was curious if you could dive into the specifics of how much the cyber attack impacted you guys in terms of revenue and EBITDA?

And then also the impact of phosphate binders inclusion in the Medicare bundle? Thank you, guys.

Yeah, so on the cyber, just to be clear, this happened in April, so there no impact in Q1. And it remains to be seen what the net impact on adjusted OI will be in Q2, but I'll remind you it's built into our guidance. Terms of, remind me of the second question, about binders. So I think if the question is how does this build up individually into our lines, our RPT was up about $10 quarter over quarter as a result of binders, and our cost per treatment was up roughly $8 for the quarter from binders.

Thank you. Our next caller is Justin Lake with Wolfe Research. You may go ahead, sir.

Hi, this is Dean Rizalis on for Justin. Thank you for the updated color on non acquired treatment growth in the year. Can you speak to your expectations for RPT in the year? Are they still in the 4.5% to 5.5% range? Thank you.

Yeah, no change to our guide on RPT for the year. We think we'll get a little bit more from orals in the bundle, as Javier mentioned, but still within the range of the guide from last quarter.

Thank you. Our next caller is Pito Chickering with Deutsche Bank. You may go ahead.

Hey guys, thanks for taking my questions here. Going back to the treatment growth question, can you sort of quantify just the new patients that started this quarter and how they're going start the tracking in 2Q and sort of how that looks sort of year over year? And are seeing any changes to mortality rate now that we're exiting the flu season?

Yeah, so starting on the admit side, Q1 was a strong admit quarter for us. And we know there was a lot of interest last quarter. We called out a weak admit quarter in Q4. And I think a lot of curiosity on was that a normal variability, which is what we suspected, or is it somehow the beginning of a trend? And the strength we saw in Q1 certainly supports the hypothesis we have that it was just normal variability.

So admits was certainly, it was in line with what we expected, but it was strong mortality in Q1, it was absolutely elevated. We think that was one hundred percent as a result of the flu. So not much more to say about that. It's a little early to see what's happening to mortality post flu. As you know, there's a little bit of a lag between when a month ends and when we have good clarity on mortality.

So I can't give you much on what happened post flu.

Okay, fair enough. And then looking at the revenue per treatment, there's sort of a bunch of pieces in there that you said that the mix was flat. You actually you had a positive tailwind obviously coming from the phosphate. Did you quantify exactly what the phosphate was to RPT? And then any other commentary in the first quarter RPT as it relates to managed care increases for this year?

And how should we think about co pays and deductibles sort of comping out in the next couple of quarters?

Yeah, I think you asked a lot of questions, but let me just sort of summarize it. We gave a range of roughly four and a half to five and a half RPT. I think just speaking in big sort of categories, half of that will be increases in the core business and half of it will be orals. And so I think that kind of bundles all your questions. Does that get to it?

Yeah, that works. And the last one here is on the IKC, a decent reduction of patients from March versus December? Just want to follow-up, think last quarter talked about some competitors out there being more aggressive on pricing. Just what are your views around the IKC patients under treatment sort of at this point and any changes probability of that versus your expectations? Thanks.

Thank you. I think a couple of things. Number one, from a clinical perspective, it's unambiguously good for patients. Our doctors are also having to change the way they practice and making sure that they start to get involved in transition of care, hospitalization and other things. So that takes a while, as we've told you, for quite some time.

The financials are playing out as expected, which is this is a business that has a bit more volatility, so we've told you to look at on an annual basis. Unfortunately, there's been several unproven entrants that have gone in there and have made some amateur risk moves and have really contracted quite poorly and aggressively. And what I mean by that is economically speaking. So we have been quite disciplined in understanding the impact that we can do to patient care, and we've been very disciplined in our financial modeling. So, while we want to, of course, earn and win more business, we wanna be able to be in a sustainable way.

And so, in addition, we've also severed some of these arrangements with some doctors that are not willing to change the way they practice, because you have to really change the way you practice to be successful at this.

Okay, great. And I'll see you guys around

Let me add one more thing to that, Pito. Some of the decline in lives that you'll see from Q4 to Q1 is also the result of our ability to better predict how many lives will be retroactively removed from attribution based on certain rules that CMS uses in the CKCC program, particularly with CKD lives. So it's not an economic change. It's more of how we count the lives and doing a better job of predicting that upfront.

Okay, the last quick one here on international that looked pretty strong. I guess any sort of good or bad guys you should highlight to us on international as you model that for the rest of year? Thank you, guys.

Yeah, international had a strong quarter. A lot of good guys across a number of markets. We feel good about how the new acquisition is playing out. We called out last quarter a $50,000,000 jump year over year and we probably picked up another 10,000,000 on top of that 50,000,000 in Q1.

Thank you. Our next caller is AJ Rice with UBS. You may go ahead, sir.

Thanks. Hi, everybody. Maybe just a couple of things. Just to follow-up on that question about the Latin America. Any update on Brazil and maybe brought more broadly on the m and a pipeline, what what you're seeing, anything to comment on what you might see in the back half of the year?

Yeah. Thanks, AJ. On the Brazil, we're pretty close, although they've given us some restrictions that we got to abide by. So we got to play that out and divest a couple centers. It's always, not a good idea to guess, but we're getting to the finish line here.

So hopefully that will be here shortly. As it relates to M and A, I think internationally continues to be an interesting place, and domestically we're still pursuing, onesie and twosies and then any practice that's willing to convert. So it's a dynamic place out there, but that's really how it summarizes.

Okay. Just to follow-up on the IKC question. The 29,000,000 loss, if I'm here making sure I heard right, that's after moving, some business that would have been a $4,000,000 a quarter drag over into the core. I guess two questions on that. It's interesting that you make that move.

What what sort of behind that? And second, do you still feel like I know we've got volatility quarter to quarter, but you're on track for a breakeven by '27 in that business.

Yeah. So just to clarify one thing, we didn't move it to the core. We moved it to other strategic initiatives. But I think the most important thing, has no bottom line impact on the enterprise. It's just moving from one business to another.

This was an IT product that when first implemented was expected to largely be used by the IKC business, but over time, it became clear that it had other utility within DaVita, including in the dialysis business. So ultimately, we decided to allocate that a little bit differently. But it has no major impact on the path to profitability. Obviously, it helps a little bit because you're just taking cost out, but within the broader context of IKC and its scale and variability, we still feel good about the path we were on.

Okay, does that then, if I could just follow-up on that then, is the 4,000,000 run rate loss it's currently had as you move it into the, this new area, does that diminish over time then?

No. I wouldn't expect it to to go down over time.

Okay. And then just maybe last point of clarification on your DNA. You're up about 3% cost for treatment. I I know you called in in the release of professional fee reductions as well as I think it's pointed to us gain of some sort. Can you just elaborate a little bit more on were those meaningful in the quarter and what was going on there?

No, I don't think there was a lot there. I think a big change in the G and A per treatment was the result of volume coming down. So there's a big treatment drop between Q4 and Q1, mostly driven by a reduction in the number of days. That was probably, I think, the single biggest thing that drove the change in G and A.

Thank you. Our next caller is Ryan Langston with TD Cowen. You may go ahead, sir.

the full year guidance the same, lowering just a little bit on the treatment volumes. I guess is a lot of that sort of the outperformance in the phosphate binder area or some of it from the stronger new set of admits that you called out?

Yeah, so if I had to break down how we're thinking about guidance, I would say there were two negatives for the quarter, or for the year. One is the decline in volume, the 50 bps. We brought that down. And the second will be the cyber costs. So those are headwinds on the year, offset by two tailwinds.

One is strength in Q1, and the second is the increase in the binders. The net impact of those two headwinds and two tailwinds would be no change.

Okay. And I might have missed the first part of AJ's question, but in the release it said there was a decrease in professional fees and then there was a gain, I think, in G and A. Can you help us size the gain again? I'm sorry if AJ asked it. And also maybe what drove the decrease in pro fees?

Yeah, these are minimal items, single digit millions. I wouldn't get too concerned about them.

Thank you. At this time, I'm showing no further questions. Speakers, I'll turn the call back over to you for closing comments.

Okay. Thank you, Michelle, and thank you all for your questions. If you've been following us, we have experienced three temporary externalities, including supply shortages due to a hurricane, a high flu season, and now a cyber incident. Regardless, we continue to achieve our clinical and financial objectives. We look forward to building momentum over the remaining of the year.

Thank you. This concludes today's conference call. You may go ahead and disconnect at this time.

DaVita (DVA) Q1 2025 Earnings Call Transcript

Company Participants